2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly ResultsZacks Investment Research • 11/10/23
Compared to Estimates, Ligand (LGND) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/09/23
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 11/01/23
Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-TermZacks Investment Research • 10/24/23
Ligand Pharmaceuticals (LGND) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 10/20/23
Will Ligand (LGND) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/09/23
Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaBusiness Wire • 09/22/23
Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active ControlBusiness Wire • 09/21/23
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose BioBusiness Wire • 09/18/23
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business Wire • 09/02/23